Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think you should sell your 300 shares and move on. Biotech doesn't seem the best place for ma and pa to invest based on risk profile. We'll be sure to write once a year to catch up. Good luck to you.
So today is payday?
You planning on picking up another 300 shares?
Are we dumb enough to resort to #prayforprurisol? No we PATENT it!
Just more proof Prurisol 2b is a failure (SARCASM)
Correct. Last trade 16:00:44
Perfect. Check please!
Maybe our future partner is taking a stake. EOM
Volume has increased since the PR was sent. Now into day 2. Maybe more than Ma and Pa are buying?
Also, another correction. The stock is currently green.
I just want to point out that this post is a contradiction...
At one point, you call the PR, "hedging, word play and obfuscation", then your next sentence says "I love the PR".
You can't have it both ways... was it "hedging, word play and obfuscation" or "love"?
I disagree. I learned several things from today's PR. I have also learned that most "pro-rated" comments are wrong.
All that highlighting, yet one thing was missed...
"if we deliver strong top-line results"
If we get similar or better results to the interim, the words collaboration, interest and conversations change to:
PARTNERSHIP
Yes, it will no longer be a question of "if", but "when".
Be careful with throwing around common sense on this board. It is likely to get attacked!
Also, I agree 100%
There is nothing wrong, with being wrong. Happens all the time. With almost certainty, even if something is "rated pro" it's probably wrong.
Short positions on IPIX will decrease shortly. Good luck!
I think today's volume is starting to show controlled covering. Good luck to you!
I think this is probable.
From what I recall from other trials:
The CRO/researchers/investigators use this time to work with the trial sites to clarify and double check certain data points before the final unblinded data is presented to the company.
To me, what is sloppy is how Leo's language is misused.
Leo has answered that question long ago. He made it crystal clear in the December 2015 shareholder meeting. The one rub with a shareholder meeting is: you have to be a shareholder to get that information.
I think it is admirable of you to admit you were wrong. We are all proud of you.
Believe it or not, doctors actually make mistakes, too. I think if me, you and a doctor sat down and chatted about IPIX, we'd learn a lot from that doctor.
Keep up the good work!
In the past 2 years, Leo posted the 10-q on 11/9, which is next week. Something else to keep in mind.
Cabel, I am less concerned when Leo PRs the OM topline data and more focused on when Leo gets it. And he may already have it.
2 things...
1) this information will help Leo decide which drug to partner first AND
2) this information will help Leo decide the future direction of the company.
In the past, for other trials, Leo has stated topline results are coming in the next few weeks, etc. In the last update on OM, he still said 4th quarter. Seems like he left himself open, maybe in case he needs some time for negotiations????
I just want to point out that your first sentence has a mistake. Numerous does not mean five. When I notice a mistake in the first sentence, I don't bother reading the rest.
Awesome! Thanks for sharing.
BP: first we wanna know if it works
Leo: check out these UP results with endoscopy
BP: nice but that's not placebo controlled
Leo: check out these OM results with placebo arm
BP: nice but is it safe
Leo: check out these from the ABSSSI trials
BP: thanks, you answered all my questions. Can we meet next week?
Leo: actually, I'm meeting with numerous others next week, how about the following week?
Read the last paragraph...no wonder he talks such shit about our company; he works for Celgene and wants our anti -inflammatories on the cheap!
Your posts are sorely missed!
How to look desperate: issue IHUB posts that say nothing new.
As the share price increases.
September 11th - "Furthermore, we are receiving significant interest in Brilacidin for inflammatory bowel disease following the successful completion of the Phase 2 proof-of concept study of Brilacidin for ulcerative proctitis/ulcerative proctosigmoiditis."
Leo and Co. are awfully quiet...
Something brewing?
Just read your first sentence and already found a mistake:
"more frequent dosing for effectiveness"
you should change this to:
"more frequent dosing for INCREASED effectiveness"
I skipped the rest because there are probably other mistakes there too.
You're welcome.
"We've actively engaged with multiple large pharmas, who have expressed an interest in Brilacidin inflammatory bowel disease. The pharma industry is quite interested in pursuing novel IBD therapies one of the more active therapeutic areas when it comes to dealmaking."
"In the meantime, we can say that big pharma knows that we know there's tremendous value in our pipeline. They know that. We work daily to position our product to command the higher value. The good news is that data will start streaming in very shortly. The bottom line is assuming the data is in line with previous data or interim results, we feel there are opportunities for partnering."
"All the conversations have been productive and as we approach additional readouts, I'd imagine that they're only going to get more active. Active partnership versus acquisition on possible exits, we plan to keep an open mind should opportunities present themselves."
"We had said that confidential disclosure agreements have been signed with several pharmas interested in our drug candidates; to some, they're interested in one compound. Others have requested information on a combination of Brilacidin and Kevetrin and Prurisol."
"Companies will pay what the drug is worth to them. Our job when it comes to partnering is to get our pipeline far enough along to present positive datasets to several potential partners and go from there. That's the point we are at currently."
This week begins the ascent. 4 weeks f/u for OM completes next week.
Couldn't agree more. Our time is a-coming!
I really think that those 58% odds are an objective number...
But for IPIX, we have to be a bit more subjective...
B-OM already has interim analysis out....PLUS...Leo has stated if OM works, they are nearly certain UP would work...UP worked, so the logic implies OM will work. Safety has been established in the ABSSSI trials...this adds up to > 58% odds for B-OM
K was a 1b, and has had an observable effect on OV cancer cells, which have the highest percentage of P53 damage... and they are targeting OV cancer in the phase 2 trial. K was safe enough that MAD was declared as MTD.
P has already completed a phase 2a and is a pro-drug of an existing approved drug.